Core Viewpoint - Merck has announced the approval of its new non-nucleoside cytomegalovirus (CMV) inhibitor, Prevymis® (Letermovir), by the National Medical Products Administration (NMPA) in China for use in pediatric patients at risk of late-onset CMV infection and disease [1] Group 1 - Prevymis® is approved for three formulations: oral tablets, injectable solution, and oral tablets (II) [1] - The drug can be used continuously for up to 200 days post-HSCT in children aged 6 months and older with a body weight of 6 kg or more [1]